Please provide your email address to receive an email when new articles are posted on . High FeNO levels indicate exacerbation and lung function risks. Most patients with high FeNO levels also had ...

Apogee Therapeutics reports early trial data showing its asthma drug APG777 sharply reduced a key inflammation marker for up ...

Phase 1b interim results of zumilokibart (APG777) in asthma demonstrated rapid and durable suppression of FeNO (key biomarker of Type 2 ...

Please provide your email address to receive an email when new articles are posted on . The treatment group had reductions in FeNO 1 week after a single dose. Reductions were significant compared with ...

SaveHealth reports seven asthma medication categories, including inhaled corticosteroids and biologics, helping manage ...

As-needed use of a metered-dose inhaler with albuterol plus budesonide (Airsupra) lowered the risk of severe exacerbations compared with albuterol alone for people with normally mild asthma, the phase ...

WILMINGTON, Del.--(BUSINESS WIRE)-- AIRSUPRA’s US Prescribing Information now includes clinically meaningful evidence from the BATURA study in patients with mild asthma. 1 The BATURA Phase IIIb trial, ...

As-needed use of albuterol–budesonide has been shown to result in a significantly lower risk of severe asthma exacerbation than as-needed use of albuterol alone among patients with moderate-to-severe ...

Severe airflow obstruction was prevalent in children and adults with asthma, especially those who were extremely preterm or small for gestational age.

(RTTNews) - AstraZeneca (AZN, AZN.L, ZEG.DE, AZN.ST) announced a major update to the U.S. prescribing information for AIRSUPRA, following new clinical evidence from the BATURA study. This Phase IIIb ...

Approximately 25 million people in the U.S. have asthma, according to the Asthma and Allergy Foundation of America. While that number shows how common the condition has become, the severe form is more ...

(MENAFN- Market Press Release) December 13, 2025 7:27 am - The Dupixent market for moderate-to-severe asthma is valued at $3.25 billion in 2025 and is projected to grow at a 14% CAGR through 2032.